M&A Deal Summary |
|
|---|---|
| Date | 2022-02-28 |
| Target | Viatris - Biosimilars |
| Sector | Life Science |
| Buyer(s) | Biocon |
| Sellers(s) | Viatris |
| Deal Type | Divestiture |
| Deal Value | 3.3B USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1978 |
| Sector | Healthcare Services |
| Employees | 16,315 |
| Revenue | 150.5B INR (2025) |
Biocon develops and sells biotechnology products for the pharmaceutical sector in India and internationally. Biocon was founded in 1978 and is based in Bengaluru, Karnataka.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: Pennsylvania M&A | 1 of 1 |
| Country: United States M&A | 2 of 2 |
| Year: 2022 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2006-04-17 |
Nobex
Research Triangle Park, North Carolina, United States Nobex Corporation was acquired by Biocon Ltd. Nobex Corporation, a drug development company, develops oral peptide therapeutics in the United States. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 1961 |
| Sector | Life Science |
| Employees | 32,000 |
| Revenue | 14.7B USD (2024) |
Viatris is a generic and specialty pharmaceutical company. Viatris offers the industry's broadest and highest quality product portfolios, a robust product pipeline, and a global commercial footprint through operations in more than 90 countries. Viatris was founded in 1961 and is based in Canonsburg, Pennsylvania.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 3 |
| Sector: Life Science M&A | 1 of 3 |
| Type: Divestiture M&A Deals | 1 of 3 |
| State: Pennsylvania M&A | 1 of 3 |
| Country: United States M&A | 1 of 3 |
| Year: 2022 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-09-08 |
Aspen Pharmacare Holdings - Thrombosis Business
United Kingdom Aspen Pharmacare's Thrombosis Business is a global offering comprised largely of a broad range of specialist injectable anticoagulants. Aspen's portfolio also includes Orgaran which is a heparin derivative (heparinoid) indicated for the treatment of HIT. HIT is an adverse reaction occurring in a limited number of patients undergoing heparin related therapy. It offers healthcare providers the advantage of a single supplier that addresses broad clinical needs and thus ensures the optimal care of patients at risk of thrombosis. |
Buy | €642M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-07-03 |
Viatris - Over the Counter Business
Canonsburg, Pennsylvania, United States Viatris - Over the Counter (OTC) Business is a global healthcare company. |
Sell | - |
